NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Yuimedi

Yuimedi

Private
TokyoHealthcare & Life Scienceshttps://yuimedi.com/

Last Round

Series A

Feb 18, 2026

Total Funding Raised

$9.59M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Yuimedi is a health-tech company that provides an AI-powered medical data infrastructure platform for cleansing, standardizing, and analyzing clinical datasets.

Sector

Healthcare & Life Sciences

Verticals

EHR & EMR, Healthcare Analytics, Data Integration, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

medical data standardizationreal world dataRWDEMR data structuringOMOP CDMclinical data cleaninghealth techmedical NLPclinical trial optimizationhealthcare interoperabilitydata pipelinedrug discoveryhealthcare analyticsdata normalizationhealth data infrastructureclinical data lake

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Yuimedi Comps

Public and private peers based on sector, stage, and business model.

Yuimedi comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Yuimedi Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 18, 2026
Early FundingJul 2, 2024
Early FundingNov 30, 2022
AcceleratorNov 29, 2022

Key People

Founding team and executive leadership

Emiri Grimes

Founder and CEO

Founding Team

Shingo Inoue

Chief Technology Officer

Executive Team

Kazuhiko Muraoka

Group CFO

Executive Team

Yuimedi Investors

Notable investors and investment history

Yuimedi investors
InvestorRounds
Darwin Venture ManagementSeries A
Sumitomo Mitsui Trust BankSeries A
D4V (Design for Ventures)Early Funding, Series A
Nissay CapitalEarly Funding
DG Daiwa VenturesEarly Funding, Series A
Norinchukin Capital Co., Ltd.Series A
Alchemist AcceleratorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2026

    Monthly visitors grew 103% MoM, reaching 5.5K.

Yuimedi Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Yuimedi Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Yuimedi's valuation, stock price, and market status.

Firmographic Details

HeadquartersTokyo
Employee Range13
Year Founded2020
Last FundingFeb 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.